Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05668403 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05668403 · ClinicalTrials.gov record · last posted 2026-04-30

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

StatusRecruiting
PhasePhase 1
Started2023-03-02
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

Amendment record 8 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 8 times since 2022-12-20; most recent amendment 2026-04-29. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-03-23
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05668403
Lead Sponsor Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborators: Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Primary Membranous Nephropathy
Enrollment 52 participants
Start Date 2023-03-02
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-30